Brief: Femasys Enrollment Over 25% Complete For Femaseed De Novo Trial
29/11/2022 12:30
Nov 29 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS INC. ANNOUNCES ENROLLMENT IS OVER 25% COMPLETE FOR
FEMASEED® DE NOVO TRIAL FOLLOWING UPDATED STRATEGIC STUDY DESIGN
Source text for Eikon: ID:nGNX6PbpNJ
Further company coverage: FEMY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Femasys
See all newsBrief: Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing
Brief: Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview